Company profile
Nuvation Bio Inc.
NYSE: NUVB · Healthcare · Biotechnology
#406 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
49DFH 49DQ 45GM —SS 64
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$143.0M
Rev growth YoY (TTM)
+1205.5%
Net income (FY)
-$204.6M
Employees
298
as of 2026-08-09
Market cap
$2.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$62.9M$62.9M2025
Net income-$204.6M-$204.6M2025
Operating income-$213.1M-$213.1M2025
Total assets$594.8M$594.8M2025
Liabilities$289.1M$289.1M2025
Equity$305.7M$305.7M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License61%
Product39%
By geography
JAPAN46%
UNITED STATES39%
CHINA15%
The read
What is Nuvation Bio Inc.’s revenue?
Nuvation Bio Inc. booked $62.9M in FY2025 revenue, growing 699% year over year — faster than 95% of Healthcare companies we track, at a -325.3% net margin.
Peers · Healthcare
Cosmos Health Inc.55CConcord Medical Services Holdings Limited59CElectromed, Inc.80B+DIH Holding US, Inc.——Sorrento Therapeutics, Inc.——Tango Therapeutics, Inc.55CNeighbors
New York →Key facts
CEODavid T. Hung
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeNYSE: NUVB
Employees298
IPO date2020-08-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.